CB2 — the immune-system receptor

TL;DR

  • Mostly on B-cells, macrophages, microglia.
  • No psychoactive signal — CB2 agonists don't make you high.
  • Anti-inflammatory effects.
  • Therapeutic target for neuropathy, fibrosis, colitis.

Why is CB2 pharmacologically interesting?

Selective CB2 agonists could deliver cannabis' anti-inflammatory and analgesic effect without CB1 psychoactivity. Phase-II trials in diabetic neuropathy and rheumatoid arthritis (Turcotte 2016).

Cellular signalling pathways and the activation of the CB2 receptor

The CB2 receptor belongs to the family of G-protein-coupled receptors and differs fundamentally in its structure from the CB1 receptor. Upon activation by endogenous endocannabinoids such as 2-arachidonoylglycerol or exogenous phytocannabinoids, the receptor initiates an intracellular signalling cascade. This inhibits adenylate cyclase and regulates the activity of ion channels as well as protein kinases. Unlike CB1 receptors, which primarily control the release of neurotransmitters in the central nervous system, the activation of CB2 mainly regulates the release of cytokines and the migration of immune cells in tissues.

This specific distribution makes the receptor a crucial modulator of the immune system in acute and chronic inflammatory reactions. Since its activation does not trigger any psychoactive effects, the research of synthetic and natural ligands is a focus of modern pharmacology. The challenge lies in developing highly selective compounds that bind exclusively to CB2 without showing cross-reactions at the CB1 receptor. This could open up new avenues in the treatment of autoimmune diseases and chronic inflammatory processes without impairing the cognitive functions of those affected.

  • Coupling to Gi/o proteins to regulate intracellular messengers.
  • Modulation of cytokine release to curb inflammatory processes.
  • No significant influence on synaptic transmission in the healthy brain.
  • Focus on selective ligands to avoid psychoactive side effects.

Swiss legal framework and medical cannabis in the focus of CB2

In Switzerland, the legal amendment of August 2022 has significantly facilitated the medical use of cannabis, as doctors are now permitted to prescribe corresponding preparations without an exceptional permit from the Federal Office of Public Health (BAG). For therapeutic procedures targeting the activation of the CB2 receptor, this opens up new clinical scope. Since cannabinoids with a total THC content of less than one percent are not subject to the Narcotics Act (BetmG), CBD-rich products are also freely available. These weakly psychoactive substances also interact indirectly with the endocannabinoid system and support the demand for standardized products.

When prescribing THC-containing medicinal products, however, patients must observe the strict Swiss road traffic regulations. A strict THC limit of 1.5 micrograms per litre of blood applies, which in practice corresponds to a zero-tolerance rule. Even if the therapeutic effect is primarily mediated via the peripheral CB2 receptors and there is no noticeable impairment, the detection of THC in the blood leads to unfitness to drive. The ongoing cantonal pilot trials on the regulated sale of cannabis are currently providing further scientific data that are also relevant for research into receptor activation in everyday life.

  • Facilitated prescription of medical cannabis by Swiss doctors since August 2022.
  • Free sale of products with a total THC content of less than one percent.
  • Strict limit of 1.5 micrograms of THC per litre of blood in road traffic.
  • Scientific monitoring through cantonal pilot trials under the supervision of the BAG.

Peripheral tissues and the therapeutic spectrum outside the immune system

In addition to classic immune cells, the CB2 receptor can also be detected in various peripheral organs such as the liver, skin, and skeletal system. In the skin, it plays an essential role in regulating cell growth and barrier function, making it of interest for dermatological research. Evidence from preclinical studies suggests that targeted stimulation of the receptor can support wound healing and dampen excessive inflammatory reactions of the skin without completely suppressing the systemic immune defense.

In bone metabolism, the CB2 receptor influences the balance between bone formation and bone resorption by modulating the activity of osteoblasts and osteoclasts. A lack of functioning receptors is scientifically associated with reduced bone density. The activation of the receptor also shows protective effects in experimental models of fibrotic changes in internal organs such as the liver or kidneys. These diverse points of action illustrate that the therapeutic potential extends far beyond pure pain relief.

  • Presence in the skin for the potential regulation of inflammation and wound healing.
  • Involvement in bone metabolism by influencing osteoblasts.
  • Protective effect against fibrotic tissue changes in internal organs.
  • Potential for the development of topical and systemic therapeutics without CNS effects.

FAQ

Is CB2 found in the brain?

Yes, at low density on microglia — upregulated in neuroinflammation (Alzheimer's, MS).

What role does the CB2 receptor play in chronic inflammatory bowel diseases?

In chronic inflammatory bowel diseases such as Crohn's disease or ulcerative colitis, the CB2 receptor is strongly upregulated in the inflamed intestinal tissue. Activation of the receptor by cannabinoids can help reduce the migration of inflammatory cells into the intestinal mucosa and inhibit the production of pro-inflammatory mediators. Although clinical data in humans are still limited, experimental studies suggest that targeting the CB2 receptor could support tissue healing and alleviate symptoms without causing the typical side effects of conventional immunosuppressive therapy.

Does the effect of CBD and THC on the CB2 receptor differ?

Yes, THC and CBD interact with the CB2 receptor in different ways. While tetrahydrocannabinol (THC) binds directly to the CB2 receptor as a weak partial agonist, cannabidiol (CBD) has a very low direct binding affinity. Instead, CBD acts more as an inverse agonist or indirectly modulates the action of other cannabinoids by inhibiting the degradation of endogenous endocannabinoids. As a result, CBD increases the concentration of endocannabinoids such as anandamide, which in turn can activate the receptors, partly explaining the anti-inflammatory properties of CBD-rich products.

Can the activation of the CB2 receptor help in pain therapy?

Activation of the CB2 receptor is considered a promising approach in pain therapy, particularly for neuropathic and inflammatory pain. Since CB2 receptors are located on immune cells and the pain-transmitting pathways of the peripheral nervous system, their activation dampens the release of inflammatory mediators that cause nerve irritation. Because these receptors are barely present in the healthy brain, the undesirable psychoactive effect that occurs when CB1 receptors are activated by THC does not occur. This enables the development of targeted pain relievers with a more favorable side-effect profile.